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Abstract 
 
Visceral adipose tissue (VAT) is an important risk factor for obesity-related metabolic 
disorders.  Therefore, a reduction in VAT has become a key goal in obesity management.  
However, VAT is correlated with intrahepatic triglyceride (IHTG) content, so it is possible that 
IHTG, not VAT, is the primary determinant of metabolic disease.  We determined the 
independent contribution of IHTG and VAT to metabolic function, by evaluating groups of 
obese subjects, who differed in IHTG content (high or normal) but matched on VAT volume, or 
differed in VAT volume (high or low) but matched on IHTG content.  Stable isotope tracer 
techniques and the euglycemic-hyperinsulinemic clamp procedure were used to assess insulin 
sensitivity and very-low-density lipoprotein-triglyceride (VLDL-TG) secretion rate.  Tissue 
biopsies were obtained to evaluate cellular factors involved in ectopic triglyceride accumulation.  
Hepatic, adipose tissue and muscle insulin sensitivity were 41%, 13% and 36% lower (P<0.01), 
whereas VLDL-triglyceride secretion rate was almost double (P<0.001), in subjects with high 
than normal IHTG content, matched on VAT.  No differences in insulin sensitivity or VLDL-TG 
secretion were observed between subjects with different VAT volumes, matched on IHTG 
content.  Adipose tissue CD36 expression was lower (P<0.05), whereas skeletal muscle CD36 
expression was higher (P<0.05), in subjects with high than normal IHTG.  These data 
demonstrate that IHTG, not VAT, is a better marker of the metabolic derangements associated 
with obesity.  Furthermore, alterations in tissue fatty acid transport are likely involved in the 
pathogenesis of ectopic triglyceride accumulation by redirecting plasma fatty acid uptake from 
adipose tissue toward other tissues. 
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Visceral adipose tissue (VAT) is an important and independent predictor of metabolic 
risk factors for coronary heart disease, particularly diabetes and dyslipidemia (1, 2).  Moreover, 
data from metabolic studies conducted in human subjects (3, 4) indicate that an increase in VAT 
is associated with impaired glucose tolerance, insulin resistance, and increased very-low-density 
lipoprotein-triglyceride (VLDL-TG) secretion.  These observations and the unique anatomical 
location of visceral fat, which releases free fatty acids (FFA) and adipokines into the portal vein 
for direct transport to the liver, have led to the concept that VAT is responsible for many of the 
metabolic abnormalities associated with abdominal obesity (5, 6).  Therefore, a reduction in 
visceral fat has become a key therapeutic goal in the management of obesity (6, 7).  
Although VAT is associated with metabolic disease, a causal link between VAT and 
metabolic dysfunction has not been demonstrated in humans.  Recently, it has become clear that 
VAT correlates directly with intrahepatic triglyceride (IHTG) content (8-10), and an increase in 
IHTG is associated with the same metabolic abnormalities linked to an increase in VAT (9-12).  
Therefore, it is possible that VAT itself is not harmful, but is simply an innocent bystander that 
tracks with IHTG.  
The mechanism(s) responsible for the interrelationship among IHTG content, insulin 
resistance and hypertriglyceridemia is not known, but could involve redirecting plasma FFA 
uptake and intracellular triglyceride production from adipose tissue depots to other tissues, such 
as liver and skeletal muscle, which can impair insulin signaling (13, 14) and stimulate VLDL-TG 
secretion (11).  Therefore, it is possible that organ-specific alterations in CD36 which regulates 
tissue FFA uptake from plasma (15), are involved in the pathogenesis of ectopic triglyceride 
accumulation and metabolic disease.  
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The purpose of the present study was to test the hypotheses that: 1) high IHTG content, 
not increased VAT volume, is the primary marker of metabolic abnormalities associated with 
obesity, and 2) high IHTG content reflects alterations in adipose tissue and skeletal muscle CD36 
gene expression and protein content that are consistent with redirecting plasma fatty acids away 
from adipose tissue and toward other metabolic organs.  Both in vivo and cellular metabolic 
assessments were conducted in obese subjects, who were carefully matched on either IHTG 
content or VAT volume, to help separate the influence of IHTG and VAT on metabolic function.  
Stable isotope tracer infusions in conjunction with mathematical modeling were used to evaluate 
hepatic, skeletal muscle and adipose tissue insulin sensitivity, and VLDL-TG secretion rate, 
while adipose tissue and skeletal muscle biopsies were used to determine cellular CD36 gene 




Body composition.  Subjects in each group were matched on age, sex, body mass index (BMI) 
and percent body fat, but differed in either IHTG content or VAT volume (Table 1).  Mean 
IHTG content in the high-IHTG groups was more than 5-fold greater than the normal-IHTG 
groups, and mean VAT volume in the high-VAT group was more than 2-fold greater than the 
low-VAT group (Table 1).   
 
Plasma metabolic variables.  Plasma insulin concentration was almost 2-fold greater and 
plasma adiponectin concentration was ~50% lower in subjects with high IHTG content than in 
those with normal IHTG who were matched on VAT volume (Table 2).  No significant 
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differences in metabolic variables were detected between subjects with low or high VAT volume 
who were matched on IHTG content (Table 2).  
 
Basal glucose and fatty acid kinetics.  Basal glucose and palmitate kinetics were not different 
between matched subjects within any of the two groups (Table 2). 
 
Insulin sensitivity.  Hepatic (Fig. 1A), skeletal muscle (Fig. 1B) and adipose tissue (Fig. 1C) 
insulin sensitivity was lower in subjects with high than in those with normal IHTG content.  
However, no differences in insulin sensitivity measures were observed between subjects with 
low or high VAT volume, when matched on IHTG content (Fig. 1).  
 
VLDL-TG kinetics.  Hepatic VLDL-TG secretion rate was almost double in subjects with high 
than in those with normal IHTG content (23 ± 2 and 12 ± 1μmol/min, respectively; P < 0.001), 
when matched on VAT volume (Fig. 2A).  However, VLDL-TG secretion rate was the same in 
subjects with either low or high VAT volume, when matched on IHTG content (Fig. 2A).   
The relative contribution of non-systemic fatty acids incorporated into newly secreted 
VLDL-TG (presumably derived from lipolysis of intrahepatic and intraperitoneal triglyceride, 
hepatic lipolysis of circulating triglyceride, and de novo hepatic fatty acid synthesis) was much 
greater in subjects with high than with normal IHTG content (58 ± 4% and 28 ± 4%, 
respectively; P < 0.001) (Fig. 2B).  The secretion rate of VLDL-TG comprised of non-systemic 
fatty acids was more than 4-fold greater in subjects with high than with normal IHTG content 
(14±2 and 3±1 μmol/min, respectively; P < 0.001), and accounted for their increase in total 
VLDL-TG secretion rate (Fig. 2A).  In contrast, the absolute secretion rate of VLDL-TG 
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comprised of systemic plasma FFA was similar in both the high and normal IHTG groups (8±1 
and 9±1 μmol/min, respectively) (Fig. 2A).  The relative contribution of fatty acids from different 
sources to total VLDL-TG production was not different between subjects with either low or high 
VAT volume, when matched on IHTG (Fig. 2B).   
 
Predictors of insulin sensitivity and VLDL-TG kinetics.  Multivariate linear regression 
analyses, which included age, sex, BMI, percent body fat, IHTG, VAT and subcutaneous 
abdominal adipose tissue volumes as independent variables, indicated that IHTG content was the 
best predictor of insulin action in liver, skeletal muscle and adipose tissue and of VLDL-TG 
secretion rate, accounting for 21%, 45%, 38%, and 21%, respectively, of the variability (P ≤ 0.01 
for each model).  VAT was not a predictor of any of the dependent variables. 
 
Muscle and adipose tissue regulation of fatty acid trafficking.  
  Skeletal muscle CD36 gene expression was almost 3-fold higher in subjects with high 
IHTG than those with normal IHTG content, matched on VAT volume (0.82 ± 0.16 and 0.34 ± 
0.05 AU; P < 0.05) (Fig. 3A).  Total and detergent-soluble muscle CD36 protein content was not 
different between any of our subject groups, but detergent-insoluble CD36 content was two-fold 
greater in subjects with high IHTG than in those with normal IHTG content (Fig. 3B).  In 
contrast, abdominal subcutaneous adipose tissue CD36 gene expression was 35% lower in the 
high IHTG than in the normal IHTG group (0.09 ± 0.01 and 0.14 ± 0.01 AU; P < 0.05) (Fig. 3C), 
and adipose tissue CD36 protein content was 43% lower in subjects with high IHTG than in 
those with normal IHTG (0.10 ± 0.03 and 0.33 ± 0.05 AU; P < 0.05) (Fig. 3D).  Plasma insulin 
concentration was inversely correlated with adipose tissue CD36 expression (r=0.56, p<0.01) 
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and directly correlated with muscle insoluble CD36 content (r=0.58, p=0.02).  No differences in 
CD36 adipose tissue gene expression and protein content and in muscle gene expression were 
detected between subjects with low or high VAT volume, when matched on IHTG content (Fig. 
3).   
 
Subgroup analysis of subjects matched on normal IHTG content with high or low VAT 
 To ensure that the metabolic alterations associated with high IHTG content did not mask 
an association between high VAT volume and metabolic dysfunction, we evaluated the subgroup 
of obese subjects who had normal IHTG content and either high or low VAT volume.  No 
differences in any metabolic variables were detected between these two groups of subjects 
(Table 3).   
 
Discussion 
Increased IHTG and VAT are important risk factors for the metabolic complications 
associated with obesity, particularly insulin resistance and dyslipidemia (1-4).  However, it is not 
known whether IHTG or VAT are independent contributors to metabolic risk because both are 
strongly correlated with each other (8-10).  In the present study, we were able to determine the 
independent contribution of IHTG and VAT to insulin action and hepatic VLDL-TG metabolism 
by evaluating metabolic function in obese, non-diabetic, subjects who were separated into 
distinct groups based on IHTG content and VAT volume. We found that insulin action in liver, 
skeletal muscle and adipose tissue was impaired and hepatic VLDL-TG secretion rate was 
increased in subjects with high IHTG content, but not in those with high VAT volume if IHTG 
content was normal.  In addition, adipose tissue CD36 mRNA and protein content were 
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decreased, whereas skeletal muscle CD36 mRNA and protein content were increased, in subjects 
with high IHTG content.  These data demonstrate that IHTG content, not VAT volume, is a 
marker of obesity-related metabolic dysfunction.  However, our data are not able to determine 
whether this association is a cause-and-effect relationship, and other mechanisms for insulin 
resistance have also been proposed (ref). Furthermore, the CD36 profile observed in different 
tissues and subject groups suggests that alterations in cellular fatty acid uptake are involved in 
the pathogenesis of ectopic triglyceride accumulation in subjects with non-alcoholic fatty liver 
disease (NAFLD), by redirecting plasma FFA uptake from adipose tissue toward other tissues.  
The results of the present study contradict the prevailing dogma that VAT has deleterious 
metabolic effects (5, 6).  Data from both large epidemiological surveys and small physiological 
studies have shown an association between increased VAT and many of the metabolic 
complications of obesity, particularly insulin resistance, diabetes, and dyslipidemia (1-4).  It has 
been hypothesized that the mechanism responsible for the adverse effects of VAT is related to 
the release of FFA and inflammatory adipokines from VAT directly into the portal vein where 
they are delivered to the liver and affect glucose (6) and VLDL-TG (16) metabolism.  However, 
a causal relationship between VAT and metabolic disease has never been established.  In fact, 
only about 20% of portal vein FFA delivered to the liver and 14% of systemic FFA delivered to 
skeletal muscle are derived from lipolysis of VAT in obese subjects (17, 18).  In addition, in vivo 
secretion rates of most adipokines from VAT are probably not greater than the secretion rates 
from subcutaneous adipose tissue (19).  Therefore, the majority of adipokines in the portal vein 
are derived from subcutaneous fat, which releases adipokines into the systemic circulation that 
enter the portal vein through the splanchnic bed.  We were able to separate the effect of VAT 
from the potentially confounding influences of total and regional adiposity and ectopic fat 
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distribution on metabolic function, by matching obese subjects with low and high VAT volume 
on BMI, percent body fat, abdominal subcutaneous adipose tissue, and IHTG content.  In 
subjects matched for IHTG content, a 2-fold difference in VAT volume between low and high 
VAT groups was not associated with detectable differences in insulin sensitivity or VLDL-TG 
secretion rate.  In contrast, subjects with high IHTG content had impaired insulin action in liver, 
adipose tissue, and skeletal muscle and increased hepatic VLDL-TG secretion rate, 
independently of VAT.  Moreover, IHTG content was the best independent predictor of 
increased VLDL-TG secretion rate and insulin resistance in all tissues, whereas VAT did not 
help explain any of the metabolic outcomes.  These data demonstrate that VAT is not an 
important contributor to the metabolic complications associated with obesity, and suggest that 
the association between VAT and metabolic disease is due to the direct correlation between VAT 
volume and IHTG content.  
The mechanism responsible for excessive triglyceride accumulation in non-adipose 
tissues (i.e., ectopic fat) is not known.  This issue has important physiological and clinical 
implications because of the association between ectopic fat and metabolic dysfunction (20).  It 
has been hypothesized that ectopic fat accumulation is caused by an inadequate capacity of 
adipose tissue to store triglyceride (21, 22).  However, it is unlikely that the small amount of 
triglyceride that accumulate in “ectopic” organs, such as liver and skeletal muscle cannot be 
accommodated by the large adipose tissue mass in obese persons.  For example, the amount of 
IHTG in our subjects with high (25%) IHTG content represented about 1% of the total 
triglyceride present in adipose tissue; on average, these subjects had ~0.4 kg of triglyceride in the 
liver and ~40 kg of triglyceride in adipose tissue.  Our data suggest a more plausible mechanism 
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for ectopic fat accumulation, which involves alterations in the regulation of FFA uptake from 
plasma by CD36.   
The importance of CD36 in FFA transport and ectopic triglyceride accumulation has been 
demonstrated by observations in human subjects indicating that increased skeletal muscle 
plasmalemma CD36 content is associated with increased muscle FFA uptake and 
intramyocellular triglyceride accumulation (23).   We found that adipose tissue CD36 expression 
and protein content were lower, while skeletal muscle CD36 expression and detergent insoluble 
protein content were higher in subjects who had high IHTG content than those who had normal 
IHTG content.  In skeletal muscle, CD36 moves between intracellular stores and the cell 
membrane.(24)  Cell membrane CD36 is mostly localized to lipid rafts/caveolae, which are 
detergent-resistant membrane domains that are important in CD36-facilitated fatty acid 
uptake.(25, 26)  Therefore, CD36 present in detergent-insoluble cell components is an indicator 
of membrane-associated CD36 available for fatty acid uptake.  The mechanism responsible for 
differences in tissue CD36 content is not known, but could be related to circulating insulin, 
because plasma insulin concentration was inversely correlated with adipose tissue CD36 
expression and directly correlated with muscle insoluble CD36 content in our subjects.  Although 
we did not determine CD36 gene expression or protein content in the liver, data from other 
studies suggest that hepatic CD36 expression was likely increased in our subjects with high 
IHTG content, because hepatic CD36 expression is directly correlated with liver fat in human 
subjects (27).  Our data suggest that alterations in cellular fatty acid transport are involved in the 
pathogenesis of ectopic fat distribution by diverting the accumulation of triglyceride away from 
adipose tissue and toward other key metabolic organs.  
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Alterations in tissue CD36 activity can also help explain the close link between ectopic 
fat accumulation and tissue insulin resistance (9, 14).  The pattern of CD36 expression and 
protein content in adipose tissue and skeletal muscle in our subjects with high IHTG content 
indicate an increase in muscle, and presumably liver, uptake of plasma FFA.  Intramyocellular 
and intrahepatocellular fatty acids that are not oxidized or exported as VLDL-TG are esterified to 
triglyceride or metabolized to intermediates that can impair insulin signaling (13, 14).  The 
potential importance of CD36 activity in regulating insulin sensitivity is supported by studies 
conducted in obese and diabetic human subjects that found that increased skeletal muscle CD36 
in human subjects is associated with increased FFA uptake and insulin resistance (23), whereas 
pharmacological stimulation of adipose tissue CD36 expression and FFA uptake by peroxisome 
proliferator-activated receptor-γ agonist therapy in patients with type 2 diabetes (28) is 
associated with a reduction in IHTG content and improvements in insulin sensitivity (21).  
A decrease in adipose tissue CD36 gene expression and protein content could also have 
contributed to steatosis and insulin resistance by affecting adiponectin metabolism.  Adiponectin 
is the most abundant secretory protein produced by adipose tissue, and has important beneficial 
metabolic effects.  Adiponectin administration decreases IHTG (29), increases hepatic insulin 
sensitivity (30), and reverses obesity-related skeletal muscle insulin resistance (31).  Adipose 
tissue adiponectin gene expression is decreased in CD36-null mice, demonstrating that adipose 
tissue CD36 activity is directly involved in the regulation of adiponectin production (32).  
Therefore, it is possible that decreased CD36 activity in adipose tissue in our subjects with high 
IHTG content led to a decrease in adiponectin secretion and low plasma adiponectin 
concentration we observed in these subjects.  Should we delete this paragraph?   
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The data from the present study support the notion that IHTG is directly involved in the 
pathogenesis of dyslipidemia associated with obesity (11).  Most triglycerides in plasma are a 
component of circulating VLDL-TG.  Therefore, VLDL-TG metabolism is involved in the 
regulation of plasma triglyceride concentrations, and increased VLDL-TG secretion rate can 
increase plasma triglyceride concentration.  The rate of hepatic VLDL-TG secretion was 2-fold 
greater in subjects with high IHTG content than in those with normal IHTG, independent of 
VAT volume.  Moreover, the increase in VLDL-TG secretion rate was entirely due to an 
increase in the contribution of non-systemic fatty acids.  Our data suggest that the increase in 
VLDL-TG secretion rate in obese subjects who have NAFLD is primarily caused by the 
availability of non-systemic fatty acids derived from lipolysis of IHTG, not VAT, because VAT 
volume was the same in both groups and de novo lipogenesis accounts for up to 20% of the fatty 
acids secreted in VLDL-TG in subjects with NAFLD (33, 34).  Therefore, it is possible that 
excessive IHTG is not only a marker of metabolic dysfunction, but also contributes to the 
increase in VLDL-triglyceride secretion rate and plasma triglyceride concentration observed in 
obese persons with NAFLD. 
In summary, increased IHTG is an independent indicator of multi-organ insulin resistance 
and increased hepatic secretion of VLDL-TG.  In addition, fatty acids released from lipolysis of 
IHTG might stimulate hepatic VLDL-TG production, demonstrating that IHTG itself is directly 
involved in the pathogenesis of dyslipidemia associated with NAFLD (11).  Our data refute the 
notion that increased VAT causes metabolic abnormalities associated with obesity, and suggest 
the commonly observed relationship between increased VAT and metabolic disease (1-4) is due 
to the correlation between VAT and IHTG (8-10).  Alterations in CD36 content in adipose tissue, 
muscle, and presumably liver, likely contribute to the association between ectopic fat distribution 
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and obesity-related metabolic disease, by redirecting fatty acid uptake from adipose tissue 
toward other metabolic organs.  These data underscore importance of increased IHTG content as 
a marker of the metabolic complications associated with obesity. 
 
Materials and Methods 
 
Subjects. A total of 42 obese men and women were screened for this study. We found that 30 
subjects from this group (71% of the screened population; mean BMI 35.6 ± 0.8 kg/m
2
) could be 
separately matched on visceral or liver fat, and therefore participated in this study.  A total of 30 
obese (BMI 35.6 ± 0.8 kg/m
2
) men and women participated in this study.  Subjects were 
distributed among two groups based on IHTG content and VAT volume to help separate the 
interrelationships between IHTG, VAT and metabolic function; 15 subjects were assigned to 
more than one group to maximize appropriate matching within groups.  Group 1 subjects (n = 
20) were matched on VAT volume and had either high (>10% of liver volume) (n = 10) or 
normal (≤5.5% of liver volume) (n = 10) IHTG content (Table 1) (35).  Group 2 subjects (n = 24) 
were matched on IHTG content and had either low (n=12) or high (n=12) VAT volume (Table 1).  
Subjects within groups were matched on age, sex, BMI, and percent body fat.  
All subjects completed a comprehensive medical evaluation, which included a 2-h oral 
glucose tolerance test.  No subject had any history or evidence of liver disease other than 
NAFLD, took medications that can affect metabolism or cause hepatic abnormalities, consumed 
more than 20 g/d of alcohol, or had diabetes.  Subjects gave their written informed consent 
before participating in this study, which was approved by the Human Research Protection Office 
of Washington University School of Medicine in St. Louis, MO. 
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Body composition analyses.  Body fat mass (FM) and fat-free mass (FFM) were determined by 
using dual-energy x-ray absorptiometry (Delphi-W densitometer, Hologic, Waltham, MA).  
Intra-abdominal and abdominal subcutaneous adipose tissue volumes were quantified by 
magnetic resonance imaging (Siemens, Iselin, NJ; ANALYZE 7.0 software, Mayo Foundation, 
MN) (9) and IHTG content was measured by using proton magnetic resonance spectroscopy 
(Siemens, Erlanger, Germany) as we have previously described (36).  
 
Hyperinsulinemic-euglycemic clamp procedure.  Subjects were admitted to the Intensive 
Research Unit at Washington University School of Medicine on the evening before the clamp 
procedure.  At 1900 h, subjects consumed a standard meal, which provided 12 kcal/kg adjusted 
body weight and contained 55% of total energy as carbohydrate, 30% as fat and 15% as protein.  
Adjusted body weight was calculated as ideal body weight (based on the midpoint of the medium 
frame of the Metropolitan Life Insurance Tables) plus 0.25 × (actual body weight minus ideal 
body weight).  A 250-kcal liquid snack (Ensure
TM
, Ross Laboratories, Columbus, OH) was 
consumed at 2000 h.  Subjects then fasted until completion of the clamp procedure the next day. 
At 0500 h the following morning, one catheter was inserted into a forearm vein to infuse 
stable isotope-labeled tracers (Cambridge Isotope Laboratories, Andover, MA), dextrose and 
insulin, and a second catheter was inserted into a radial artery in the contralateral hand to obtain 
blood samples.  Radial artery cannulation was not successful in 5 subjects, so a catheter was 
inserted into a hand vein, which was heated to 55°C by using a thermostatically controlled box, 
to obtain arterialized blood samples (11).  At 0600 h, a primed, continuous infusion of [6,6-
2
H2]glucose, and a continuous infusion of [2,2-
2
H2]palmitate, were started, as previously 
  15 
described (37).  After infusion of the tracers for 3.5 hours (basal period), a two-stage 
euglycemic-hyperinsulinemic clamp protocol was started and continued for 6 hours.  Insulin was 
infused at a rate of 20 mU·m
-2
 body-surface area (BSA)·min
-1









 for 5 min) during stage 1 (3.5 to 













 for 5 min) during stage 2 of the clamp 
procedure (5.5 to 9.5 h).  These two insulin infusion rates were chosen to evaluate adipose tissue 
insulin sensitivity (low-dose insulin infusion to submaximally suppress adipose tissue lipolysis) 
and skeletal muscle insulin sensitivity (high-dose insulin infusion to stimulate muscle glucose 
uptake) (38).  Euglycemia (5.6 mmol/L; 100 mg/dL) was maintained by infusing 20% dextrose 
enriched to 2.5% with [6,6-
2





H2]palmitate were reduced by 50% during stage 1, and [6,6-
2
H2]glucose infusion was 
reduced by 75% during stage 2 of the clamp procedure to account for changes in hepatic glucose 
production and lipolytic rates.   
Tissue samples were obtained from subcutaneous abdominal adipose tissue and from the 
quadriceps femoris muscle 60 min after starting the glucose tracer infusion (basal stage).  The 
biopsy sites were cleaned and draped, and muscle and adipose tissues were obtained under sterile 
conditions.  After anesthetizing the skin and underlying tissues with lidocaine, adipose tissue was 
aspirated from the periumbilical area by using a 14-gauge needle and skeletal muscle was 
obtained by using Tilley-Henkel forceps (Sontec Instruments Inc., Centennial, CO) inserted 
through a small (0.5 cm) skin incision. Tissue samples were immediately rinsed with ice-cold 
saline, and frozen in liquid nitrogen, before being stored at -80°C.   Blood samples were obtained 
before beginning the tracer infusion to determine background plasma glucose and palmitate 
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tracer-to-tracee ratios (TTRs), and every 10 min during the final 30 min of the basal period and 
stages 1 and 2 of the clamp procedure to determine glucose, FFA and insulin concentrations and 
substrate kinetics.  These blood samples were collected in chilled tubes containing sodium 
EDTA.  Samples were placed on ice, plasma was separated by using refrigerated centrifugation 
within 30 min of collection and then stored at -80ºC until final analyses were performed.  Blood 
was also obtained every 10 min during insulin infusion to monitor plasma glucose 
concentrations.  
 
VLDL-TG kinetics study.  One week after the hyperinsulinemic-euglycemic clamp procedure, 
subjects were readmitted to the Intensive Research Unit on the evening before the VLDL kinetics 
study.  At 1800 h, subjects consumed the same standard meal and snack as before the clamp 
procedure, and then fasted, except for water, until the completion of the isotope infusion study 
the next day. 
At 0500 h the following morning, a catheter was inserted into a forearm vein to infuse 
stable isotope-labeled tracers (Cambridge Isotope Laboratories, Andover, MA).  A second 
catheter was inserted into a contralateral hand vein, which was heated to 55°C by using a 
thermostatically controlled box to obtain arterialized blood samples (11).  At 0600 h, a bolus of 
[1,1,2,3,3-
2




) was started and maintained for 12 hours.   
Blood samples were obtained before and at 5, 15, 30, 60, 90, and 120 min, and then every 
hour for the remaining 10 h, after the start of the isotope infusion to determine glycerol and 
palmitate TTRs in plasma and in VLDL-TG.  Blood was immediately placed in chilled tubes 
containing EDTA to determine substrate concentrations and TTRs.  Samples were placed on ice, 
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and plasma was separated by centrifugation within 30 min of collection.  Aliquots of plasma (2 
mL) were refrigerated at 4°C for subsequent isolation of VLDL; the remaining plasma samples 
were stored at -80°C until final analyses were performed. 
 
Analyses of samples.  Plasma glucose concentration was measured by using an automated 
glucose analyzer (Yellow Spring Instruments Co, Yellow Springs, OH).  Plasma insulin 
concentration was measured by using a chemiluminescent immunoassay method (Immulite 1000, 
Diagnostic Products Corporation, Los Angeles, CA).  Plasma adiponectin concentration was 
measured by using an ELISA kit (Linco Research, St. Louis, MO).  Plasma FFA concentration 
was determined by using gas chromatography (39).  Plasma VLDL was prepared as previously 
described (40, 41) and VLDL-TG concentration was determined by using an enzymatic 
spectrophotometric kit (Sigma Chemical, St. Louis, MO).  Plasma glucose, palmitate, and 
glycerol TTRs in plasma and in VLDL-TG were determined by using electron impact ionization 
gas chromatography-mass spectrometry, as previously described (40-42).   
CD36 gene expression was determined by using quantitative real-time PCR. Total RNA 
was isolated from muscle and adipose tissues by using either RNAzol B (muscle, Tel-test) or 
Trizol (adipose, Invitrogen).  RNA was quantified by using spectrophotometry (NanoDrop 1000) 
and cDNA was synthesized using Taqman Reverse Transcription Kit (Applied Biosystems).  
cDNA samples were then amplified by using SYBR Green PCR Master Mix (Applied 
Biosystems) on the ABI 7500 Real-Time PCR System (Applied Biosystems).  Results were 
analyzed by comparing the threshold crossing (Ct) of each sample after normalization to the 
housekeeping 36B4 gene (DCt).  The changes in the threshold crossing (DCt) were used to 
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calculate the relative levels of each mRNA compared to control gene from the various samples 
using the formula 2
-DCt
.  Primer pairs used for transcript detection were: 
Gene Forward Reverse 
CD36 GAGACCTGCTTATCCAGAAGACAAT TTCTGTGCCTGTTTTAACCCAATTTTT 
36B4 GTGATGTGCAGCTGATCAAGACT GATGACCAGCCCAAAGGAGA 
 
Total CD36 protein, and muscle detergent-soluble and detergent-insoluble CD36 
(generated from muscle lysates containing 1% Triton) were determined by western blot(43) and 
protein detection by infrared imaging technology (LI-COR Biosciences).  β-Αctin was used to 
normalize CD36 protein intensity levels. 
 
Calculations.  Glucose and palmitate kinetics. Isotopic steady-state conditions were achieved 
during the final 30 min of the basal period and stages 1 and 2 of the clamp procedure, so Steele’s 
equation for steady-state conditions was used to calculate substrate kinetics (44). It was assumed 
that glucose rate of disappearance (Rd) from plasma was equal to glucose rate of appearance 
(Ra) during basal conditions; during the clamp procedure glucose Rd was assumed to be equal to 
the sum of endogenous glucose Ra and the rate of infused glucose. Palmitate kinetics were 
expressed in μmol/kg FM per min to provide an index of adipose tissue lipolytic activity in 
relation to the amount of endogenous fat stores, and in μmol/kg FFM per min to provide an index 
of FFA availability for lean tissues that use fatty acids for fuel. 
VLDL-TG kinetics. The fractional turnover rate (FTR) of VLDL-TG (in pools/h) and 
hepatic VLDL-TG secretion rate into plasma (in μmol/min) was calculated by fitting the glycerol 
TTR in plasma and VLDL-TG to a multi-compartmental model as previously described (42, 45). 
  19 
The proportion of fatty acids within VLDL-TG derived from systemic plasma FFA (generated by 
lipolysis of subcutaneous adipose tissue triglyceride) and non-systemic fatty acids (generated by 
lipolysis of intrahepatic and intraperitoneal triglyceride, hepatic lipolysis of circulating 
triglyceride, and/or de novo hepatic fatty acid synthesis) was calculated by accounting for 
isotopic dilution between plasma and VLDL-TG palmitate by using a multi-compartmental 
model (11). 
Insulin sensitivity. Hepatic insulin sensitivity was determined by calculating the 
reciprocal of the Hepatic Insulin Resistance Index (defined as the product of basal endogenous 
glucose production rate, in μmol·kg FFM-1·min-1 and fasting plasma insulin concentration in 
mU/L) (46).  Adipose tissue and skeletal muscle insulin sensitivity were assessed as the relative 
decrease in palmitate Ra during stage 1 and the relative increase in glucose Rd during stage 2 of 
the euglycemic-hyperinsulinemic clamp procedure, respectively (9). 
 
Statistical analyses.  All data sets were normally distributed according to the Kolmogorov-
Smirnov test, so comparisons between subjects within each grouping (i.e., between subjects who 
had same VAT volume but either normal or high IHTG content, and subjects who had the same 
IHTG content but different VAT volume) were performed by using parametric procedures.  
Levene’s test was used to assess the equality of group variances on each dependent variable, and 
Student’s t-test for unpaired samples was used to compare results between groups.  Multiple 
stepwise linear regression analysis (with age, sex, BMI, percent body fat, IHTG content, VAT 
and subcutaneous abdominal adipose tissue volumes as independent variables) was performed to 
identify significant independent predictors of metabolic outcomes.  Results are presented as 
means ± SEM.  A P-value ≤ 0.05 was considered statistically significant.  Analyses were 
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performed by using SPSS 16.0 (SPSS Inc., Chicago, IL).
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Figure legends 
 
Figure 1.  Hepatic (A), skeletal muscle (B) and adipose tissue (C) insulin sensitivity in subjects 
matched on visceral adipose tissue (VAT) volume with either normal or high intrahepatic 
triglyceride (IHTG) content, and subjects matched on IHTG content who had low or high VAT 
volumes. Values are means ± SEM. *Value is significantly different from the corresponding 
value in normal IHTG group, P < 0.05.  
 
Figure 2.  Very low-density lipoprotein-triglyceride (VLDL-TG) secretion rate (A) and the 
relative contribution of systemic (generated primarily by lipolysis of subcutaneous adipose tissue 
triglycerides) and non-systemic fatty acids (generated primarily by lipolysis of intrahepatic 
triglycerides) to VLDL-TG production (B) in subjects matched on visceral adipose tissue (VAT) 
volume with either normal or high intrahepatic triglyceride (IHTG) content, and in subjects 
matched on IHTG content who had low or high VAT volume.  Values are means ± SEM.  
*Value is significantly different from corresponding value in the normal IHTG group, P < 0.001.   
 
Figure 3.  Skeletal muscle (A) and subcutaneous abdominal adipose tissue (C) CD36 gene 
expression, skeletal muscle (B) and adipose tissue CD36 protein content (D) in subjects matched 
on visceral adipose tissue (VAT) volume with either normal or high intrahepatic triglyceride 
(IHTG) content, and in subjects matched on IHTG content who had low or high VAT volume.  
Values are means ± SEM.  *Value is significantly different from corresponding value in the 
normal IHTG group, P < 0.05.  
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Table 1.  Subject characteristics in each study group 
Variable 
Group 1: matched on 
VAT 







Low VAT High VAT 
n (M/F) 10 (3/7) 10 (3/7) 12 (3/9) 12 (3/9) 
Age (yr) 44 ± 2 36 ± 3 40 ± 3 44 ± 3 





36.3 ± 1.5 34.9 ± 1.4 36.2 ± 1.3 
Body fat (% body 
weight) 
41 ± 2 39 ± 2 42 ± 2 41 ± 2 
IHTG (% liver 
volume) 
3.7 ± 0.6 25.3 ± 3.5* 13.3 ± 4.1 13.1 ± 3.9 














3954 ± 371 3618 ± 413 3309 ± 268 
Values are means ± SEM.   
*Value is significantly different from the corresponding value in the normal IHTG group, P < 0.01; and 
†value is significantly different from the corresponding value in the low VAT groups, P < 0.05. 
IHTG, intrahepatic triglyceride; VAT, visceral adipose tissue, SAAT, subcutaneous abdominal adipose 
tissue volume 
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Table 2.  Metabolic variables and basal substrate kinetics 




High IHTG Low VAT High VAT 
Glucose (mg/dL) 95 ± 2 97 ± 3 97 ± 2 95 ± 2 
Insulin (mU/L) 12 ± 1 21 ± 3* 14 ± 2 15 ± 2 
Total adiponectin (μg/mL) 7.85 ± 1.02 4.25 ± 0.32* 7.39 ± 1.28 6.41 ±0.79 
Free fatty acids (mmol/L) 0.43 ± 0.04 0.45 ± 0.03 0.47 ± 0.03 0.51 ± 0.03 
Total triglyceride (mg/dL) 108 ± 12 136 ± 18 108 ± 13 130 ± 15 
VLDL-triglyceride (mmol/L) 0.55 ± 0.13 0.69 ± 0.13 0.57 ± 0.10 0.60 ± 0.10 
Total cholesterol (mg/dL) 156 ± 13 163 ± 6 161 ± 7 159 ± 12 
LDL-cholesterol (mg/dL) 97 ± 8 91 ± 7 91 ± 6 99 ± 8 
HDL-cholesterol (mg/dL) 46 ± 4 45 ± 5 49 ± 2 42 ± 4 
Glucose Ra (μmol·kg FFM-1·min-1) 14.2 ± 0.4 13.6 ± 0.6 14.0 ± 0.5 14.0 ± 0.6 
Palmitate Ra (μmol·kg FM-1·min-1) 3.5 ± 0.4 3.1 ± 0.3 3.0 ± 0.2 3.1 ± 0.3 
Palmitate Ra (μmol·kg FFM-1·min-1) 2.2 ± 0.2 2.1 ± 0.2 2.0 ± 0.3 2.0 ± 0.2 
Values are means ± SEM.   
*Value is significantly different from the corresponding value in the normal IHTG group, P < 0.01. 
To convert the values for glucose to mmol/L, multiply by 0.05551.  To convert the values for insulin to 
pmol/L, multiply by 6.  To convert the values for cholesterol to mmol/L, multiply by 0.0259.  To convert 
the values for triglycerides to mmol/L, multiply by 0.0113.  
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Table 3.  Body composition and metabolic characteristics of subjects with low or high VAT 
and normal IHTG content. 
Variable Matched on normal IHTG 
 Low VAT High VAT 
n (M/F) 7 (2/5) 7 (2/5) 
Body mass index (kg/m2) 34.8 ± 1.9 35.8 ± 2.0 
Body fat (% body weight) 42 ± 3 40 ± 3 
IHTG content (% liver volume) 3.7 ± 0.7 3.4 ± 0.6 
VAT volume (cm3) 744 ± 104 1474 ± 317* 
Hepatic Insulin Sensitivity Index  
[1/(μmol·kg FFM-1·min-1x mU/L)] 
0.67 ± 0.1 0.67 ± 0.1 
Insulin-mediated stimulation of glucose Rd (%) 297 ± 37 294 ± 35 
Insulin-mediated suppression of palmitate Ra (%) 71 ± 2 71 ± 2 
VLDL-triglyceride secretion rate (μmol /min) 12.9 ± 2.1  10.9 ± 1.5 
Skeletal muscle CD36 mRNA (AU) 0.31 ± 0.06 0.35 ± 0.06 
Skeletal muscle CD36 insoluble protein (AU) 0.23 ± 0.07 0.27 ± 0.10 
Adipose tissue CD36 mRNA (AU) 0.13 ± 0.01 0.14 ± 0.01 
Adipose tissue CD36 protein content (AU) 0.40 ± 0.07 0.33 ± 0.08 
Values are means ± SEM.   
*Value is significantly different from the corresponding value in the Low VAT group, P < 0.05. 
IHTG, intrahepatic triglyceride; VAT, visceral adipose tissue; VLDL, very low-density lipoprotein. 
 
 
 
 
 
